GLP3-RT — Weight Management (titration)
glp3-rt is a GLP-1/GIP/glucagon triple agonist (retatrutide-class) — a once-weekly protocol where the slow dose ladder, not a fixed cycle, IS the protocol.
Why this protocol
glp3-rt hits three incretin/metabolic receptors at once: glp-1 (curbs appetite, boosts insulin), gip, and glucagon (raises energy expenditure). In its Phase 2 obesity trial that combination produced large weight reductions — roughly −17% to −24% body weight at 48 weeks across the 4, 8, and 12 mg/week target doses.
The defining feature is the titration. You start very low and step up only as gastrointestinal tolerance allows — the dose ladder is the protocol. Going too fast is the main cause of nausea and dropout, so patience at each step matters more than reaching a target quickly.
Investigational compound — the doses are the Phase 2 trial ladder, and weight figures are trial findings, not a promise. Doses match the GLP3-RT page; titrate by GI tolerance. No therapeutic claims.
The regimen
GLP3-RT
Triple agonist (GLP-1/GIP/glucagon)- Dose
- Start 1 mg/week → 4 / 8 / 12 mg/week targets
- Schedule
- Once weekly · subcutaneous
- Timing
- One consistent day each week; time of day is flexible
Reconstitution calculator
Reconstitution calculator
Calculated for a 1 mL U-100 insulin syringe (100 units/mL).
Units per dose
80
Draw to this mark on a U-100 syringe
- Volume per dose
- 0.8 mL
- Doses per vial
- 2
- Concentration
- 5 mg/mL
One vial lasts
- Daily
- 2 days
- Every other day
- 5 days
- 5×/week
- 3 days
- Large draw (80 units). Double-check the vial size and dose — a mcg/mg mix-up produces values like this.
Research use only. Not for human consumption. Outputs are reference values based on research literature — verify all measurements independently.
Cycle & schedule
Titration (from 1 mg/week)
Begin at 1 mg once weekly — starting this low is non-negotiable. Hold each dose step until GI tolerance is established before moving up; starting escalation days with a light, low-fat meal helps.
Target run (toward 48 weeks)
Escalate by tolerance toward a 4, 8, or 12 mg/week target (the Phase 2 doses; higher targets drove larger weight change). The trial effect builds over ~48 weeks at the target dose.
Studies behind this protocol
This protocol composes the cited evidence on each peptide's page — see the full bibliography on: GLP3-RT.
Research use only · Not medical advice · Updated 2026-06-01